Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Long-Term Extension (LTE) Study of Mavacamten

Trial Profile

A Long-Term Extension (LTE) Study of Mavacamten

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mavacamten (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions; Registrational
  • Acronyms Mava-LTE
  • Sponsors MyoKardia
  • Most Recent Events

    • 24 Oct 2018 According to a MyoKardia media release, the patient dosing has been started in this study. Up to 280 patients who successfully complete either MAVERICK-HCM or EXPLORER-HCM clinical trials will be eligible for enrollment in this study.
    • 24 Oct 2018 Status changed from planning to recruiting, according to a MyoKardia media release.
    • 17 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top